bet365-bet365在线平台bet365

网络博彩排名买球平台推荐 游戏与赌博 最大赌博 澳门太阳城娱乐 九州官方
跳到主要内容
回到顶部
奥古斯塔大学 Logo

信息:

  • 当前的学生
  • 校友
  • 社区
  • 教职员工
  • 军事
  • 病人

资源

  • a - z指数
  • 日历
  • bet365
  • 网站LMS
  • 电子邮件
  • 库
  • MyAugusta
  • 新闻
  • 工作和职业
  • 门户网站
  • 突袭
  • 航天飞机
  • 招生
  • 学者
  • 关于
  • bet365在线平台
  • 体育运动
  • 研究
  • 健康
  • 给
完整性和安全性
  • 利益冲突
  • 研究安全
  • 质量评审及监察
  • 研究人员的工具
  • 奥古斯塔大学
  • 研究
  • 完整性和安全性
  • 人体受试者研究的质量评价监测

人体受试者研究的质量评价监测

Investigator-initiated trials (IITs) provide an innovative pathway for scientific advancements that 奥古斯塔大学 strives to support. The 研究 Integrity & Security Monitoring Service was created to proactively provide risk-based oversight for IITs, and other human research studies, as a method for building a robust network of institutional and investigational compliance.

监控服务概述

研究诚信与安全监控服务旨在:

  • 评估并促进对法律、法规、政策和协议的遵从
  • 保护研究参与者的权利和安全
  • 鼓励数据完整性
  • 支持和鼓励奥古斯塔大学在人类学科研究方面的卓越研究

Monitoring reviews will be implemented routinely throughout the course of human research studies at 奥古斯塔大学, with the highest priority being given to IITs, particularly those without independent monitors. For FDA-regulated trials, monitoring will often begin once the first subject is enrolled.

This program is complimentary to and does not replace the essential roles of AU’s Human 研究 Protection Program or the Institutional Review Board (IRB) of record for your study. Furthermore, these reviews are not intended to replace standard quality assurance reviews by the PI and their research team.

研究 完整性和安全性 (RIS) Monitoring Service will provide reviews of multiple factors, including (but not limited to) regulatory documents and subject cases.

监管审查

  • IRB批准并遵守批准的协议
  • 调查员和工作人员资格证书和培训文件; Delegation of Duties Log
  • IND/IDE支架要求
  • 核实报告事件的适当和及时的报告
  • 符合PRMC和DSMC评审
  • 设备问责
  • 监控/审核文件
  • 遵守安全和保密要求
  • Oncore合规

个案审查

  • 知情同意
  • 资格
  • 治疗/干预
  • 响应/结果
  • 毒性
  • 数据质量
  • 后续
  • 计费合规
  • Oncore合规

fda监管的临床试验

In the United States, the Food and Drug Administration (FDA) is charged with the governance, oversight, and regulation of clinical trial conduct and public health protection. The agency’s regulations and guidance aim to promote safe and effective development and approval of medical drugs, biologics, and devices. A key component of these goals surrounds the approval processes for investigational drugs and devices. Investigational drugs and investigational devices are approved for experimental use by the FDA under 21 CFR 312 (Investigational New Drug Application) or 21 CFR 812 (Investigational Device Exemptions).

Below outlines current FDA regulations governing human subject protection and the conduct of clinical trials:

药物或设备

  • 21 CFR 11-电子记录和电子签名
  • 21 CFR 50-保护人类受试者(知情同意)
  • 21 CFR 54-临床研究者的财务披露
  • 21 CFR 56-机构审查委员会

药物或生物制剂

  • 21 CFR 210- Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs
  • 21 CFR 211-现行药品生产质量管理规范
  • 21 CFR 312-研究性新药申请
  • 21 CFR 314-申请FDA批准上市新药
  • 21 CFR 320-生物利用度和生物等效性要求
  • 21 CFR 330- Over-The-Counter (OTC) Human Drugs Which Are Generally Recognized as Safe and Effective and Not Misbranded
  • 21 CFR 601-生物制剂许可
  • 确定是否可以在没有IND的情况下进行人体研究(FDA指南)

设备

  • 21 CFR 807- Establishment Registration and Device Listing for Manufacturers and Initial Importers of Devices
  • 21 CFR 812-研究器械豁免
  • 21 CFR 814-医疗器械上市前批准
  • 21 CFR 820-质量体系法规
  • 21 CFR 860-医疗器械分类程序
  • 重大风险和非重大风险医疗器械研究(FDA指南)

联系我们

Laura A. Meyer Chapman, MA, RBP

706-446-1459

[email protected]

奥古斯塔15街1120号,邮编30912

Sponsor-Investigator需求

A sponsor-investigator is an individual who both initiates and conducts an investigation, and under whose immediate direction the investigational drug or device is administered or dispensed. Sponsor investigators are responsible for satisfying the regulatory requirements of both an investigator and a sponsor.

担保人责任(21 CFR 312和21 CFR 812)

监督

  • 选择合格的调查员和监督员
  • 药品/器械管制(供应和运输)
  • 通知调查员(即调查员手册和新的安全更新)
  • 审查正在进行的调查(监测和正在进行的临时安全/数据评估)

记录的保存和保留

  • Drug/设备问责 (records showing receipt, shipment, or other disposition & reservations of test articles/reference standards)
  • 临床协议
  • 研究者陈述书及个人简历
  • 财务披露资料
  • 通信文件

报告要求(向FDA)

  • IND/ IDE批准
  • 方案修订(新方案、方案变更、新研究者等)
  • 安全报告 (见FDA指南INDs和BA/BE研究的安全报告要求)
  • 年度报告
  • ClinicalTrials.gov 注册和更新(42 CFR 11)

调查员职责(21 CFR 312和21 CFR 812)

监督

  • IRB审查的保证
  • 选择/培训合格的研究人员
  • 试行与合规
  • Drug/Device Control (limiting distribution/use/ administration to research subjects & ensuring proper disposition)

记录的保存和保留

  • 药品/器械责任制(使用和处置记录)
  • Case Histories (signed consent forms, applicable medical records, and other research source documents)
  • 通信文件

报告要求(向保荐人)

  • 进度报告
  • 安全报告(不良事件/影响)
  • 最终报告
  • 财务披露报告

常见问题(FAQs)

如何选择研究进行研究完整性和安全性审查?

RIS监测服务将优先考虑具有高风险特征的研究。 没有独立监督的印度理工学院将得到最高优先考虑。 Other studies that may be prioritized include studies where investigators hold the IND/IDE, phase I clinical trials, high enrolling clinical trials, multi-site clinical trials, studies with vulnerable populations, and federally funded studies without external monitoring. RIS Monitoring is applicable to all human research studies conducted at 奥古斯塔大学 but is not required to include all studies meeting criteria for possible review.

研究者将从研究诚信与安全审查中获得什么?

RIS reviews aim is to build a robust network of institutional and investigational compliance. RIS monitor(s) apply a regulatory and compliance perspective during these reviews creating an environment for increased knowledge and understanding of applicable human subjects research regulations and 奥古斯塔大学 policies.

研究者应该如何为研究诚信与安全审查做准备?

RIS监督员将联系首席研究员(PI)安排RIS审查。 项目负责人应尽一切努力安排审查并及时作出答复。 After the review has been scheduled, the PI will be notified of the necessary review preparations. 简而言之,需要收集研究记录以供审查。 For remote reviews, RIS monitor(s) will need to be able to access required documents. For in-person reviews, the PI/study team will need to reserve a quiet space for the review to occur.

研究者对研究诚信与安全审查的期望是什么?

The scope of RIS reviews may vary and will be tailored to the scope, nature, and complexity of the research studies being reviewed. A study representative should be available to respond in a timely manner during the review. A close-out meeting will be held to discuss any findings and the PI will receive a copy of the final report. The PI is responsible for correcting any identified items and submitting the appropriate notifications of protocol deviations or violations to the IRB of record. Please note: RIS review is not intended to be comprehensive for all subjects and all items, and it does not replace standard quality assurance reviews by the PI and their research team.

研究诚信与安全监控服务是IRB的一部分吗?

不可以,RIS监察服务是独立于审核委员会的。 This program is complimentary to and does not replace the essential roles of the IRB of record for your study, or AU’s Human 研究 Protection Program. The Monitoring Service is designed to provide early-intervention and proactive monitoring for human subjects research at Augusta University.

University Shield

奥古斯塔大学

佐治亚州奥古斯塔市第15街1120号30912

  • bet365
  • 校园联系人
  • 所有的目录
  • bet365平台
  • 就业
  • 可访问性
  • 认证
  • 校园安全
  • 合规热线
  • 拐卖人口公告
  • 隐私声明
  • 第九条/不当性行为
马上申请 给现在

© 奥古斯塔大学

脸谱网 推特 LinkedIn Youtube Instagram
©
沙巴体育官网 优博娱乐 万博体育 全球十大赌钱软件排行 赌博导航 足彩皇冠 网络博彩推荐大全 365ASIA 皇冠博彩官网平台入口 体育博彩排名亚洲博彩网站